Publications by authors named "Matthew A Gubens"

Claim this Profile
A
Adjuvant chemotherapy for stage IA-IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial.
David R Spigel, Virginie Westeel, Ian C Anderson, Laurent Greillier, Florian Guisier, Matthew A Gubens

Lancet Respir Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 7.2025.
Gregory J Riely, Douglas E Wood, Dara L Aisner, Billy W Loo, Andrea L Axtell, Matthew A Gubens

J Natl Compr Canc Netw· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Associations of frailty with survival, hospitalization, functional decline, and toxicity among older adults with advanced non-small cell lung cancer.
Howard J Lee, John Boscardin, Louise C Walter, Alexander K Smith, Harvey J Cohen, Matthew A Gubens

Oncologist· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thymomas and Thymic Carcinomas, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.
Gregory J Riely, Douglas E Wood, Billy W Loo, Dara L Aisner, Wallace Akerley, Matthew A Gubens

J Natl Compr Canc Netw· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of Stage III Non-Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update Clinical Insights.
Navneet Singh, Martin Früh, Matthew A Gubens, Nofisat Ismaila, Megan E Daly

JCO Oncol Pract· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events.
Pooja Middha, Rohit Thummalapalli, Zoe Quandt, Karmugi Balaratnam, Eduardo Cardenas, Matthew A Gubens

J Immunother Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Appropriate Use Criteria (AUC) for the Management of Non-Small Cell Lung Cancer in a Central/Ultra-Central Location: Guidelines from the American Radium Society.
Henry S Park, Andreas Rimner, Arya Amini, Joe Y Chang, Stephen G Chun, Matthew A Gubens

J Thorac Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
American Radium Society Appropriate Use Criteria on Cardiac Toxicity Prevention and Management After Thoracic Radiotherapy.
Arya Amini, Vlad G Zaha, Eman Hamad, Pamela K Woodard, Andreas Rimner, Matthew A Gubens

J Thorac Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study.
Collin M Blakely, Anatoly Urisman, Matthew A Gubens, Claire K Mulvey, Greg M Allen

J Clin Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Biomarker Test Ordering Practices in Non-Small Cell Lung Cancer: Interphysician Variation and Association With Clinical Outcomes.
Jason M Baron, Sarrah Widatalla, Matthew A Gubens, Farah Khalil

JCO Precis Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
American Radium Society Appropriate Use Criteria for Unresectable Locally Advanced Non-Small Cell Lung Cancer.
George Rodrigues, Kristin A Higgins, Andreas Rimner, Arya Amini, Joe Y Chang, Matthew A Gubens

JAMA Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events.
Pooja Middha, Rohit Thummalapalli, Zoe Quandt, Karmugi Balaratnam, Eduardo Cardenas, Matthew A Gubens

medRxiv· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology.
Gregory J Riely, Douglas E Wood, David S Ettinger, Dara L Aisner, Wallace Akerley, Matthew A Gubens

J Natl Compr Canc Netw· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Guidelines® Insights: Mesothelioma: Pleural, Version 1.2024.
James Stevenson, David S Ettinger, Douglas E Wood, Dara L Aisner, Wallace Akerley, Matthew A Gubens

J Natl Compr Canc Netw· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis.
Pooja Middha, Rohit Thummalapalli, Michael J Betti, Lydia Yao, Zoe Quandt, Matthew A Gubens

Nat Commun· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival outcomes for lung neuroendocrine tumors in California differ by sociodemographic factors.
Claire K Mulvey, Alan Paciorek, Farhana Moon, Paige Steiding, Brandon Shih, Matthew A Gubens

Endocr Relat Cancer· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis.
Pooja Middha, Rohit Thummalapalli, Michael J Betti, Lydia Yao, Zoe Quandt, Matthew A Gubens

medRxiv· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
David S Ettinger, Douglas E Wood, James Stevenson, Dara L Aisner, Wallace Akerley, Matthew A Gubens

J Natl Compr Canc Netw· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
American Radium Society Appropriate Use Criteria for Radiation Therapy in the Multidisciplinary Management of Thymic Carcinoma.
Stephen G Chun, Andreas Rimner, Arya Amini, Joe Y Chang, Jessica Donington, Matthew A Gubens

JAMA Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results.
Martin Gutierrez, Wei-Sen Lam, Matthew D Hellmann, Matthew A Gubens, Charu Aggarwal

Nat Med· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023.
David S Ettinger, Douglas E Wood, Dara L Aisner, Wallace Akerley, Jessica R Bauman, Matthew A Gubens

J Natl Compr Canc Netw· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osimertinib in NSCLC With Atypical -Activating Mutations: A Retrospective Multicenter Study.
Jingran Ji, Jacqueline V Aredo, Andrew Piper-Vallillo, Laura Huppert, Julia K Rotow, Matthew A Gubens

JTO Clin Res Rep· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study.
David J Benjamin, Shuai Chen, Joanna B Eldredge, Shiruyeh Schokrpur, Debory Li, Matthew A Gubens

JTO Clin Res Rep· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC.
Matthew S Lara, Matthew A Gubens, Bianca Bacaltos, Lea Daran, Steffany L Lim

JTO Clin Res Rep· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
David S Ettinger, Douglas E Wood, Dara L Aisner, Wallace Akerley, Jessica R Bauman, Matthew A Gubens

J Natl Compr Canc Netw· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis